Westerkirk Capital’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Westerkirk Capital's VRTX Position: Q2 2026 in Review
Westerkirk Capital increased its Vertex Pharmaceuticals (VRTX) stake by 12% in Q2 2026, buying an estimated $266K and bringing the position to 5,402 shares worth $2.68M. The position accounts for 0.26% of the portfolio, ranked #62.
Westerkirk Capital first reported a position in VRTX in Q2 2025 and has held it in 5 quarters since. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Westerkirk Capital held 5,402 shares of Vertex Pharmaceuticals worth $2.68M as of Q2 2026.
- Westerkirk Capital bought 600 Vertex Pharmaceuticals shares in Q2 2026, an estimated $266K.
- Vertex Pharmaceuticals made up 0.26% of Westerkirk Capital's portfolio in Q2 2026, its #62 holding.
- Westerkirk Capital first reported a position in Vertex Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
- 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Westerkirk Capital's 13F filing for Q2 2026, filed 10 Aug 2026.